National Institute of Allergy and Infectious Diseases
  National Institutes of Health
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Tuberculosis
 What is TB?
 TB Basics
 Research
  Research Goals
  NIAID Labs
  Networks, Consortia, and Partners
  Resources
  Research Training
  Meeting Summaries
  Publications
  Feature Stories
   Introduction to TB
   TB in History
   About the TB Bug
   Understanding TB
   Diagnosing TB
   Treating TB
   Preventing TB
   Global Problem


Tuberculosis (TB)

Preventing TB

Comprehensive strategies to control and eventually eliminate TB involve many interconnected components, including developing new vaccines. NIAID is providing support to help identify new candidate TB vaccines and immune-boosting vaccine adjuvants to prevent infection or disease and is evaluating the potential of synthetic vaccines to help shorten TB drug treatment regimens.

In addition, NIAID funds vaccine development, including preclinical animal studies and clinical research on those candidate TB vaccines that appear most promising. Several candidates that demonstrated protection against infection with M. tuberculosis in small animal models have entered human clinical trials.  

Research Feature Stories

Improving a Tried and True Vaccine—BCG for the 21st Century

 How Microarrays May Lead to Better Vaccines

 Closing In: The Long Road to a TB Vaccine

 A Whiff of Protection: Mucosal Vaccines

 Beating the World’s Most Successful Bug


Highlights

March 24, 2007
Statement of Christine F. Sizemore, Ph.D., Barbara E. Laughon, Ph.D., and Anthony S. Fauci, M.D. on World TB Day

Sept. 12, 2006
Statement: Successful Public-Private Partnership Between NIAID and Sequella Yields Promising New TB Drug for Clinical Testing

E-mail Icon E-mail this page
Print Icon Print this page

Highlights

March 24, 2007
Statement of Christine F. Sizemore, Ph.D., Barbara E. Laughon, Ph.D., and Anthony S. Fauci, M.D. on World TB Day

Sept. 12, 2006
Statement: Successful Public-Private Partnership Between NIAID and Sequella Yields Promising New TB Drug for Clinical Testing